AstraZeneca signs $2 bln agreement with Quell to develop cell therapies

AstraZeneca signs $2 bln agreement with Quell to develop cell therapies The agreement includes developing, manufacturing and commercialising cell therapies that have the potential to be curative in type 1 diabetes and inflammatory bowel disease indications. https://ift.tt/jLN6SH4